Interstitial pressure of subcutaneous nodules in melanoma and lymphoma patients: changes during treatment - PubMed (original) (raw)
Clinical Trial
. 1993 May 15;53(10 Suppl):2204-7.
Affiliations
- PMID: 8485703
Clinical Trial
Interstitial pressure of subcutaneous nodules in melanoma and lymphoma patients: changes during treatment
B D Curti et al. Cancer Res. 1993.
Abstract
Interstitial pressure (IP) is a physiological variable that may have its greatest influence on the transport of high-molecular-weight therapeutic agents. IP in tumor nodules was measured in patients with metastatic melanoma or non-Hodgkin's lymphoma to determine the influence of this physiological variable on treatment outcome. The wick-in-needle technique was used to measure IP at time points before and after treatment with a variety of immunotherapy and chemotherapy regimens. Selected patients had IP measurements during chemotherapy or immunotherapy infusions. Ultrasound or computed tomography was used to evaluate the size of the studied lesions and their relationship to normal structures. The mean baseline IP in melanoma nodules (n = 22) and lymphoma nodules (n = 7) was 29.8 and 4.7 mm Hg, respectively (P = 0.013 for the difference between tumor types). In a subset of melanoma nodules for which IP had been measured before and after treatment, the IP increased significantly over time for nonresponding melanoma lesions from a baseline of 24.4 to 53.9 mm Hg after treatment (P = 0.005) and decreased in melanoma lesions that responded to treatment where the mean baseline and post-treatment IPs were 12.2 and 0 mm Hg, respectively (P = 0.001 for the difference in IP profiles between responding and nonresponding lesions). Six of seven lymphoma nodules responded completely to chemotherapy or radiation. The single nodule that did not respond had a baseline IP of 1 mm Hg that increased to 30 mm Hg after treatment. Tumor IP differs significantly between melanoma and non-Hodgkin's lymphoma. The changes in IP over time differ significantly between responding and nonresponding melanoma lesions. IP that increases during treatment appears to be associated with tumor progression in these tumor types.
Similar articles
- [Treatment option and outcome for patients with primary non-Hodgkin's lymphoma of the nasal cavity].
Yao B, Li YX, Song YW, Jin J, Liu YP, Wang WH, Wang SL, Sun YT, Yu ZH, Liu XF. Yao B, et al. Zhonghua Zhong Liu Za Zhi. 2006 Jan;28(1):58-61. Zhonghua Zhong Liu Za Zhi. 2006. PMID: 16737624 Chinese. - Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
Lee DS, White DE, Hurst R, Rosenberg SA, Yang JC. Lee DS, et al. Cancer J Sci Am. 1998 Mar-Apr;4(2):86-93. Cancer J Sci Am. 1998. PMID: 9532410 Clinical Trial. - Value of radiation therapy in the management of chemoresistant intermediate grade non-Hodgkin's lymphoma.
Aref A, Narayan S, Tekyi-Mensah S, Varterasian M, Dan M, Eilender D, Karanes C, al-Katib A. Aref A, et al. Radiat Oncol Investig. 1999;7(3):186-91. doi: 10.1002/(SICI)1520-6823(1999)7:3<186::AID-ROI8>3.0.CO;2-2. Radiat Oncol Investig. 1999. PMID: 10406061 - Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.
Dawson LA, Saito NG, Ratanatharathorn V, Uberti JP, Adams PT, Ayash LJ, Reynolds CM, Silver SM, Schipper MJ, Lichter AS, Eisbruch A. Dawson LA, et al. Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):208-18. doi: 10.1016/j.ijrobp.2003.07.004. Int J Radiat Oncol Biol Phys. 2004. PMID: 15093918 Clinical Trial. - Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB. Hagemeister FB. Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. doi: 10.1007/s00280-002-0447-1. Epub 2002 Apr 12. Cancer Chemother Pharmacol. 2002. PMID: 12042984 Review.
Cited by
- Potential of optimal preloading in anti-CD20 antibody radioimmunotherapy: an investigation based on pharmacokinetic modeling.
Kletting P, Meyer C, Reske SN, Glatting G. Kletting P, et al. Cancer Biother Radiopharm. 2010 Jun;25(3):279-87. doi: 10.1089/cbr.2009.0746. Cancer Biother Radiopharm. 2010. PMID: 20578833 Free PMC article. - Intratumoral drug delivery with nanoparticulate carriers.
Holback H, Yeo Y. Holback H, et al. Pharm Res. 2011 Aug;28(8):1819-30. doi: 10.1007/s11095-010-0360-y. Epub 2011 Jan 7. Pharm Res. 2011. PMID: 21213021 Free PMC article. Review. - Non-invasive imaging of barriers to drug delivery in tumors.
Hassid Y, Eyal E, Margalit R, Furman-Haran E, Degani H. Hassid Y, et al. Microvasc Res. 2008 Aug;76(2):94-103. doi: 10.1016/j.mvr.2008.06.002. Epub 2008 Jun 27. Microvasc Res. 2008. PMID: 18638494 Free PMC article. - Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer.
Malik P, Phipps C, Edginton A, Blay J. Malik P, et al. Pharm Res. 2017 Dec;34(12):2579-2595. doi: 10.1007/s11095-017-2259-3. Epub 2017 Sep 18. Pharm Res. 2017. PMID: 28924691 Review. - Architectural heterogeneity in tumors caused by differentiation alters intratumoral drug distribution and affects therapeutic synergy of antiangiogenic organoselenium compound.
Rustum YM, Tóth K, Seshadri M, Sen A, Durrani FA, Stott E, Morrison CD, Cao S, Bhattacharya A. Rustum YM, et al. J Oncol. 2010;2010:396286. doi: 10.1155/2010/396286. Epub 2010 Apr 27. J Oncol. 2010. PMID: 20445750 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Other Literature Sources
Medical